Can't find what you're looking for?
View all search resultsCan't find what you're looking for?
View all search resultsAn experimental vaccine being developed by AstraZeneca and Oxford University against the new coronavirus produced an immune response in early-stage clinical trials, data showed on Monday, preserving hopes it could be in use by the end of the year.
A vaccine against the coronavirus developed by CanSino Biologics Inc and China's military research unit appears to be safe and induced immune responses in most subjects in a closely-watched mid-stage study, researchers said on Monday.
Bangladesh has approved the third-phase trial of a potential COVID-19 vaccine developed by China's Sinovac Biotech Ltd, officials said on Monday, as infections continue to rise in the densely-populated South Asian country.
A Russian institute developing one of the country's potential coronavirus vaccines hopes to start its final stage testing in a small section of the general public in mid-August, the RIA news agency cited the institute's director as saying on Monday.
Thai researchers plan to begin human trials of a potential vaccine for the new coronavirus in November and are preparing 10,000 doses, a senior official said on Sunday, aiming for a vaccine that could be ready for use by late next year.
China is forging ahead in the race to develop a vaccine to help control the COVID-19 pandemic, with Sinovac Biotech's experimental vaccine set to become the country's second and the world's third to enter final stage testing later this month.
The leaders for two of the most advanced vaccine projects -- one from Oxford University, in partnership with AstraZeneca labs, and one from China's Sinovac -- will carry out Phase Three tests, the last one before the drug is approved, on thousands of Brazilian volunteers.
A COVID-19 vaccine developed by German biotech firm BioNTech and US pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.
Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.
Thank you for sharing your thoughts. We appreciate your feedback.